Press releases

26 April, 2016

Regulatory

NeuroVive starts preclinical TBI program in collaboration with PENN

NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, announces the start of the first study in the preclinical program in traumatic brain injury (TBI) which is being done in col ...

18 April, 2016

Regulatory

NeuroVive: large shareholder to participate in the rights issue

NeuroVive Pharmaceutical AB (publ) announces that Baulos Capital Belgium SA, one of the largest shareholders, intends to participate in the upcoming rights issue.

11 April, 2016

Regulatory

NeuroVive strengthens its organization with the recruitment of Cecilia Hofvander as IR and Communications Director

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that it has recruited Cecilia Hofvander as Investor Relations and Communications Director effective from 1 June 2016 i ...

31 March, 2016

Regulatory

NeuroVive Pharmaceutical AB (publ): report from EGM

Today, 31 March 2016, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company"). A summary of the resolutions follows. All resolutions were passed ...

29 March, 2016

Regulatory

Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 4 p.m. on Thursday, 28 April 2016 at Medicon V ...

14 March, 2016

Regulatory

NeuroVive announces the CiPRICS study enrols 100 patients and reports favourable safety evaluation

NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, announces that the independent safety committee has once again endorsed the continuation of the ongoing Phase II CiPRICS (Ci ...

29 February, 2016

Regulatory

Notice of extraordinary general meeting in NeuroVive Pharmaceutical AB (publ)

The shareholders in NeuroVive Pharmaceutical AB (publ) reg. no. 556595-6538 (the "Company") are hereby convened to the extraordinary general meeting, held at 10.00 a.m. on Thursday, 31 March 2016 at ...

23 February, 2016

Regulatory

Board Selects New CEO Erik Kinnman to Lead NeuroVive

NeuroVive Pharmaceutical AB (publ) board of directors is pleased to announce that it has selected Erik Kinnman as NeuroVive's Chief Executive Officer (CEO). Erik Kinnman will assume the new role on th ...

13 January, 2016

Regulatory

NeuroVive enters strategic collaboration with University of Pennsylvania

Lund, Sweden, 12 January 2016 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that it has entered into a research partnership with University of Pennsylvania to enh ...

19 November, 2015

Regulatory

NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study

Lund, Sweden, 19 November 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the independent safety committee has endorsed the continuation of the on-going P ...

2 November, 2015

Regulatory

NeuroVive Presents Findings Targeting Complex I Deficiency at World Mitochondria Congress

Lund, Sweden, 2 November 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces the presentation of preclinical data from its Complex I deficiency discovery program a ...

28 October, 2015

Regulatory

NeuroVive Aims to Find Path Forward in Antiviral Development Following Discontinuation of OCB-030 Preclinical Program by Arbutus

Lund, Sweden, 28 October 2015- NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that they will seek to find a suitable path forward to continue the development of the ...